Smoking Increases Risk of Side Effects, Recurrence in Prostate Cancer
the Cancer Therapy Advisor take:
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer, according to a study published in BJU International.
Michael Zelefsky, MD, and colleagues at the Memorial Sloan Kettering Cancer Center in New York City examined 2,358 patients with prostate cancer who underwent external-beam radiotherapy (EBRT) between 1988 and 2005. They classified patients as never smokers, current smokers, former smokers, or current smoking unknown.
They found that with a median follow-up of about 8 years, current smokers were at a 40 percent increased risk of prostate cancer relapse, along with a two-times increased risk of cancer spread and cancer-related death, compared to never smokers.
Additionally, current and former smokers had a higher likelihood of experiencing side effects such as urinary toxicity that are related to radiotherapy.
“Our findings point to the importance of physicians counseling their patients regarding the potential harms of smoking interfering with the efficacy of therapies ad for increased risks of side effects,” Dr. Zelefsky noted.
Smoking increases risks for side effects and recurrence in patients being treated for prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk